Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease
Stopped EBO-301 truncated Phase 3 study (n=97) misses primary endpoint; results unable to confirm clinical efficacy observed in Phase 2 study.
Conditions
- MAC Lung Disease
- Treatment Refractory MAC Lung Disease
Interventions
- DRUG: Epetraborole
- DRUG: Placebo
Sponsor
AN2 Therapeutics, Inc